Mingyue Optical Lens Co (301101) Fair Value & Analysis
Healthcare · CN · Market cap 6.0B CNY
Fair value as of: Jul 9, 2026
From 24 valuation models · updated 32 days ago
Share price +4.5% over the past month.
A solid business, but screening 29% overvalued on our models.
What matters now
- A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (¥25.80). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
56‑month range ¥18.39 – ¥62.06 · fair‑value band ¥15.46 – ¥25.80 · the ¥29.53 price screens above the ¥21.06 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Mingyue Optical Lens Co (301101) currently trades at ¥29.53, while our model-based Fair Value estimate is ¥21.06, implying the stock looks roughly 28.7% overvalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Mingyue Optical Lens Co generated revenue of 864M CNY at a net margin of 23.4%. Revenue grew 18.3% year over year. It earns a return on equity of 11.7%. The stock trades on a trailing P/E of 29.7. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥15.46 (bear case) to ¥25.80 (bull case); at ¥29.53, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -29%, 301101 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (¥20.00) versus Asset-Based (¥5.86). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Mingyue Optical Lens Co.,Ltd. engages in the research and development, design, and production of lenses, lens raw materials, finished mirrors, frames, and other products in China and internationally.
Full company description
Mingyue Optical Lens Co.,Ltd. engages in the research and development, design, and production of lenses, lens raw materials, finished mirrors, frames, and other products in China and internationally. The company offers high refractive index, dual blue light protection, PMC super bright, KR super tough, polarized, intelligent color changing, and progressive multifocus lenses; and customized functional products, such as juvenile myopia management, KR super toughness, smart color change, progressive multifocal, anti-fatigue, high degree of high astigmatism, postoperative protection, outdoor polarized myopia sunglasses, and other product series. It also engages in wholesale and retail trade; and technology promotion and application service industry. Mingyue Optical Lens Co.,Ltd. was founded in 2002 and is based in Danyang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Mingyue Optical Lens Co reported revenue of ¥828M in FY2025 versus ¥576M in FY2021, a compound +9.5%/yr. Reported net income was ¥193M in FY2025, compounding +23.8%/yr from FY2021.
301101 screens 29% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Mingyue Optical Lens Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mingyue Optical Lens Co (301101) overvalued or undervalued?
What is the fair value of 301101?
What is the quality score of 301101?
What is the revenue of Mingyue Optical Lens Co (301101)?
What is the net profit margin of 301101?
Does Mingyue Optical Lens Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Mingyue Optical Lens Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.